Free Trial
→ Nvidia’s Next Big Move Comes on Feb. 26 (From Weiss Ratings) (Ad)

Equillium Q4 2022 Earnings Report

Equillium logo
$0.88 -0.01 (-1.12%)
As of 02/21/2025 03:55 PM Eastern
Earnings HistoryForecast

Equillium EPS Results

Actual EPS
$0.08
Consensus EPS
-$0.33
Beat/Miss
Beat by +$0.41
One Year Ago EPS
N/A

Equillium Revenue Results

Actual Revenue
$15.76 million
Expected Revenue
$26.00 million
Beat/Miss
Missed by -$10.24 million
YoY Revenue Growth
N/A

Equillium Announcement Details

Quarter
Q4 2022
Date
3/23/2023
Time
N/A

Conference Call Resources

Equillium Earnings Headlines

Equillium reports positive Phase 2 ulcerative colitis study data
February 6, 2025 | msn.com
Equillium announces itolizumab study achieves secondary endpoint
February 6, 2025 | markets.businessinsider.com
Nvidia’s Next Big Move Comes on Feb. 26
Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of companies partnering with Nvidia on its latest AI Superproject … Companies we refer to as Nvidia's "Silent Partners" … And they could benefit greatly as well on Feb. 26.
February 22, 2025 | Weiss Ratings (Ad)
Equillium stock rallies 26% on itolizumab study data
February 6, 2025 | msn.com
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
February 6, 2025 | finance.yahoo.com
Equillium CFO Jason Keyes sells $6,500 in stock
January 24, 2025 | msn.com
See More Equillium Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Equillium? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Equillium and other key companies, straight to your email.

About Equillium

Equillium (NASDAQ:EQ), a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

View Equillium Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles